Hence, the antiparkinsonian efficacy of GUO might in fact be related to A2AR function, thus its relationship with A2AR blockade should be further investigated as previously done while assessing similar non-dopaminergic approaches to PD therapy (Kase et al., 2003; Coccurello et al., 2004). The gene discussed is ADORA2A; the disease is Parkinson disease.